Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-11-09 00:00:00 ET · period of report 2022-11-07 · accession 0001787306-22-000073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-09 | 2022-11-07 | ARQT | Watanabe Todd Franklin | See Remarks, Dir | S - Sale | $18.00 | -1,000 | 379.9K | -0.3% | -$18.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-07 | S | D | 1,000 | $18.00 | 379,907 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $17.94 to $18.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Includes 109,925 Restricted Stock Units. |